Calliditas Therapeutics AB - ESG Rating & Company Profile powered by AI
The ESG rating for Calliditas Therapeutics AB indicates the company's reporting of the United Nations SDGs. The webpage is a free ESG assessment covering Calliditas Therapeutics AB. Full ESG assessment of Calliditas Therapeutics AB can be reached by signing up for free.
Calliditas Therapeutics AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.3; made up of an environmental score of 6.0, social score of 8.0 and governance score of 4.8.
6.3
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
402 | United Laboratories International Holdings Ltd | 6.4 | High |
402 | Zenabis Global Inc | 6.4 | High |
427 | Calliditas Therapeutics AB | 6.3 | High |
427 | Carna Biosciences Inc | 6.3 | High |
427 | Atara Biotherapeutics Inc | 6.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Calliditas Therapeutics AB have an accelerator or VC vehicle to help deliver innovation?
Does Calliditas Therapeutics AB disclose current and historical energy intensity?
Does Calliditas Therapeutics AB report the average age of the workforce?
Does Calliditas Therapeutics AB reference operational or capital allocation in relation to climate change?
Does Calliditas Therapeutics AB disclose its ethnicity pay gap?
Does Calliditas Therapeutics AB disclose cybersecurity risks?
Does Calliditas Therapeutics AB offer flexible work?
Does Calliditas Therapeutics AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Calliditas Therapeutics AB disclose the number of employees in R&D functions?
Does Calliditas Therapeutics AB conduct supply chain audits?
Does Calliditas Therapeutics AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Calliditas Therapeutics AB conduct 360 degree staff reviews?
Does Calliditas Therapeutics AB disclose the individual responsible for D&I?
Does Calliditas Therapeutics AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Calliditas Therapeutics AB disclose current and / or historical scope 2 emissions?
Does Calliditas Therapeutics AB disclose water use targets?
Does Calliditas Therapeutics AB have careers partnerships with academic institutions?
Did Calliditas Therapeutics AB have a product recall in the last two years?
Does Calliditas Therapeutics AB disclose incidents of discrimination?
Does Calliditas Therapeutics AB allow for Work Councils/Collective Agreements to be formed?
Has Calliditas Therapeutics AB issued a profit warning in the past 24 months?
Does Calliditas Therapeutics AB disclose parental leave metrics?
Does Calliditas Therapeutics AB disclose climate scenario or pathway analysis?
Does Calliditas Therapeutics AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Calliditas Therapeutics AB disclose the pay ratio of women to men?
Does Calliditas Therapeutics AB support suppliers with sustainability related research and development?
Does Calliditas Therapeutics AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Calliditas Therapeutics AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Calliditas Therapeutics AB involved in embryonic stem cell research?
Does Calliditas Therapeutics AB disclose GHG and Air Emissions intensity?
Does Calliditas Therapeutics AB disclose its waste policy?
Does Calliditas Therapeutics AB report according to TCFD requirements?
Does Calliditas Therapeutics AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Calliditas Therapeutics AB disclose energy use targets?
Does Calliditas Therapeutics AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Calliditas Therapeutics AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Calliditas Therapeutics AB
These potential risks are based on the size, segment and geographies of the company.
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.